MiMedx Group (MDXG) AI Stock Analysis

• Market Cap: $1.02B
• Dividend Yield: N/A
• Average Volume (3M): 643.57K
• Price to Earnings (P/E): 31.9
• Beta (1Y): 0.81
• Revenue Growth: 6.85%
• EPS Growth: -67.67%
• Country: US
• Employees: 837
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.11
• Shares Outstanding: 147,959,410
• 10 Day Avg. Volume: 482,652
• 30 Day Avg. Volume: 643,570
• PEG Ratio: -0.84
• Price to Book (P/B): 7.32
• Price to Sales (P/S): 4.05
• P/FCF Ratio: 21.92
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 2.23
• Enterprise Value/Gross Profit: 2.74
• Enterprise Value/Ebitda: 16.30
• 1Y Price Target: $12.00
• Price Target Upside: 77.78% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 68 Neutral
• Price Target: $7.50 ▲(11.11% Upside)

MiMedx Group's overall stock score is driven by strong earnings call performance and solid financial health, despite some profitability pressures and valuation concerns. The company's strategic initiatives and raised guidance indicate confidence in future growth, though potential challenges from regulatory changes and legal expenses remain.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for MiMedx's products, enhancing its market position and supporting long-term expansion.

Cash Generation

Effective cash generation supports operational flexibility and strategic investments, crucial for sustaining growth and innovation.

Product Innovation

The launch of new products like EPIXPRESS demonstrates MiMedx's commitment to innovation, potentially driving future revenue and market share.

Negative Factors

Medicare Reimbursement Uncertainty

Regulatory changes in Medicare reimbursement could affect pricing and profitability, posing a risk to MiMedx's financial performance.

Profitability Pressure

Declining profit margins may indicate cost pressures or competitive pricing, potentially impacting long-term profitability and financial health.

Legal and Regulatory Expenses

Ongoing legal expenses can strain resources and distract management, potentially affecting operational efficiency and strategic focus.

MiMedx Group Business Overview & Revenue Model

Company Description

MiMedx Group, Inc. (MDXG) is a biotechnology company focused on the development and commercialization of regenerative medicine products based on human amniotic membrane. The company operates primarily in the healthcare sector, specializing in advanced wound care and surgical biologics. MiMedx's core products include allograft tissue products that are used to treat chronic and acute wounds, as well as surgical applications, aimed at enhancing healing and improving patient outcomes.

How the Company Makes Money

MiMedx generates revenue primarily through the sale of its regenerative medicine products, which are marketed to hospitals, outpatient surgical centers, and clinics. Key revenue streams consist of direct sales of allograft tissue products used in wound care and surgical procedures. The company benefits from strategic partnerships with healthcare providers and distributors that help expand its market reach. Additionally, MiMedx may receive reimbursements from insurance companies for its products, further contributing to its earnings. The company's focus on innovation and clinical evidence supporting the efficacy of its products also plays a significant role in driving sales and attracting new customers.

MiMedx Group Financial Statement Overview

Summary

MiMedx Group has shown strong revenue growth and improved profitability, with a robust gross profit margin of 81.9% and a positive net profit margin of 11.4%. The balance sheet is solid with a low debt-to-equity ratio, and cash flow generation is strong, indicating financial stability and flexibility.

Income Statement

MiMedx Group has shown strong growth in revenue over the observed periods, with a notable increase from $267.8M in 2022 to $352.4M in TTM (Trailing-Twelve-Months) 2025. Gross profit margin is robust at 81.9% for TTM, indicating efficient cost management. The net profit margin has turned positive, reaching 11.4% in TTM 2025 from negative figures in previous years, signaling improved profitability. However, the decline in EBIT from 2024 to TTM 2025 suggests some operational cost challenges.

Balance Sheet

The company's balance sheet reflects a solid equity position with an equity ratio of 74.98% in TTM 2025, indicating a strong capital structure. The debt-to-equity ratio is very low at 0.01, showcasing minimal leverage, which reduces financial risk. Return on equity is positive at 19.81%, reflecting efficient use of equity to generate profits. Nonetheless, the high level of cash reserves relative to debt suggests missed opportunities for investment or growth.

Cash Flow

MiMedx Group demonstrates strong cash flow generation with free cash flow growing significantly, highlighted by a free cash flow of $68.7M in TTM 2025. The operating cash flow to net income ratio is favorable, indicating efficient cash generation from operations. Furthermore, the free cash flow to net income ratio of 1.71 signifies robust cash conversion efficiency. Overall, the cash flow position is solid, underpinning financial stability and flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	363.77M	348.88M	321.48M	267.84M	258.62M	248.23M
Gross Profit	296.30M	288.81M	266.84M	219.53M	215.33M	208.90M
EBITDA	49.82M	64.34M	40.52M	-10.69M	-1.89M	-45.76M
Net Income	32.17M	42.42M	67.44M	-30.20M	-10.29M	-49.28M
Balance Sheet
Total Assets	291.11M	263.92M	239.05M	171.43M	187.93M	202.03M
Cash, Cash Equivalents and Short-Term Investments	118.87M	104.42M	82.00M	65.95M	87.08M	95.81M
Total Debt	18.46M	24.84M	48.10M	48.59M	48.13M	47.70M
Total Liabilities	74.48M	70.81M	96.33M	189.42M	187.85M	202.18M
Stockholders Equity	216.62M	193.11M	142.72M	-17.99M	82.00K	-150.00K
Cash Flow
Free Cash Flow	61.34M	64.52M	24.79M	-20.58M	-5.45M	-34.82M
Operating Cash Flow	60.16M	66.20M	26.77M	-17.89M	-1.98M	-30.26M
Investing Cash Flow	-3.95M	-9.58M	-2.15M	-2.66M	-3.40M	-4.55M
Financing Cash Flow	-4.34M	-34.20M	-8.57M	-580.00K	-3.35M	61.56M

MiMedx Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDXG, the sentiment is Positive. The current price of 6.75 is below the 20-day moving average (MA) of 6.83, below the 50-day MA of 6.97, and below the 200-day MA of 7.20, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 60.89 is Neutral, neither overbought nor oversold. The STOCH value of 78.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MDXG.

MiMedx Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDXG	―	$1.02B	31.90	16.62%	―	6.85%	-67.67%
PHAR	―	$916.82M	―	-3.40%	―	22.68%	42.45%
MAZE	―	$1.54B	―	―	―	―	―
ATAI	―	$1.51B	―	―	―	―	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORIC	―	$1.30B	―	-43.82%	―	―	-7.33%

MiMedx Group Corporate Events

MiMedx Group Reports Strong Q3 2025 Financial Results

MiMedx Group Inc., a leader in the healthcare sector, specializes in providing innovative solutions for wound care, burn, and surgical applications. The company recently reported its financial performance for the third quarter of 2025, highlighting a significant increase in net sales and net income compared to the previous year. Key financial metrics showed a 35% growth in net sales, reaching $113.7 million, with a notable rise in both wound and surgical product sales. The company’s gross profit margin improved to 83.5%, driven by favorable production variances and product mix. Looking ahead, MiMedx Group remains focused on expanding its product portfolio and navigating potential changes in reimbursement policies, aiming to sustain its growth trajectory in the healthcare market.

MiMedx Group Reports Record Q3 2025 Revenue Growth

MiMedx Group reported a record revenue of $114 million for the third quarter of 2025, marking a 35% increase from the previous year, driven by significant growth in its Wound and Surgical franchises. The company is preparing for potential changes in Medicare and Medicaid reimbursement rules, which it believes will stabilize the industry and benefit stakeholders, while maintaining a positive long-term outlook.

The most recent analyst rating on (MDXG) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.

MiMedx Group Joins Cantor Global Healthcare Conference

MiMedx Group announced its participation in the Cantor Global Healthcare Conference on September 3, 2025, and updated its investor presentation. The company is poised to expand its market presence with a focus on growth outside the U.S., increased funding for research, and an expanded product portfolio. The announcement highlights MiMedx’s strategic priorities, including product diversification and enhancing customer intimacy, which are expected to drive growth and profitability. The company also emphasizes its commitment to advocating for Medicare spending reform and leveraging favorable market trends to boost its financial performance.

The most recent analyst rating on (MDXG) stock is a Buy with a $8.50 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.

MiMedx Group Inc. Reports Record Earnings and Growth

The latest earnings call from MiMedx Group Inc. paints a picture of robust financial health and strategic progress, despite some challenges on the horizon. The company reported record revenue and EBITDA figures, underscoring strong growth in key segments. While regulatory changes and trial enrollment issues pose potential hurdles, the overall sentiment remains positive, buoyed by the company’s solid financial standing and enhanced guidance.

MiMedx Reports Record Q2 2025 Financial Results

MiMedx Group Inc. is a leader in the healthcare sector, specializing in wound care, burn, and surgical products, with a focus on innovation to improve patient outcomes.

MiMedx Group Reports Record Q2 2025 Financial Results

MiMedx Group announced record financial results for the second quarter of 2025, with net sales reaching $99 million, a 13% increase from the previous year. The company achieved its highest quarterly net sales, driven by growth in its Wound and Surgical franchises, and reported a net income of $10 million. MiMedx also raised its net sales growth expectations for 2025, anticipating low double-digit growth. The company is engaging with CMS on proposed reimbursement reforms for skin substitutes, which could impact future operations and market positioning.

The most recent analyst rating on (MDXG) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.